Ambeed.cn

首页 / / / / MBX-2982

MBX-2982 99%

货号:A882623

MBX-2982是一种选择性、口服可用的 GPR119 激动剂,用于治疗 2 型糖尿病。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
MBX-2982 化学结构 CAS号:1037792-44-1
MBX-2982 化学结构
CAS号:1037792-44-1
MBX-2982 3D分子结构
CAS号:1037792-44-1
MBX-2982 化学结构 CAS号:1037792-44-1
MBX-2982 3D分子结构 CAS号:1037792-44-1
规格 价格 库存 数量
50μL*10mM(DMSO) ¥129随货¥99 现货 - +
100μL*10mM(DMSO) ¥209随货¥149 现货 - +
250μL*10mM(DMSO) ¥419 现货 - +
500μL*10mM(DMSO) ¥699 现货 - +
10mM*1mL(DMSO) ¥1043 现货 - +
1mg ¥386 现货 - +
5mg ¥850 现货 - +
10mg ¥1436 现货 - +
50mg ¥4914 现货 - +
购物车 收藏 询单

MBX-2982 纯度/质量文件 产品仅供科研

货号:A882623 标准纯度: 99%
批次查询: 批次纯度:

全球学术期刊中引用的产品

ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]
Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]
JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]
bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]
Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]
更多 >

MBX-2982 生物活性

描述 G protein-coupled receptor 119 (GPR119), a class A G protein-coupled receptor (GPCR), is involved in regulating metabolic homoeostasis, with GPR119 agonists targeted for the treatment of type-2 diabetes and obesity. MBX-2982 is a selective, orally-available GPR119 agonist. In cells pretreated with MBX-2982 (1 μM) in “chronic incubation/washout” experiments, cAMP accumulation was significantly increased compared to control cells and the sustained response after “chronic incubation/washout” was high at 84.62 ± 20.22% of acute response. In GLUTag cells, MBX-2982 (1 μM; 120 min) evoked a statistically significant increase in GLP-1 secretion compared to control cells[3]. In C57BL/6 mice, MBX-2982 at a dose of 10 mg/kg increased the plasma GLP-1 levels without a glucose load[4].

MBX-2982 参考文献

[1]Hothersall JD, Bussey CE, et al. Sustained wash-resistant receptor activation responses of GPR119 agonists. Eur J Pharmacol. 2015 Sep 5;762:430-42.

[2]Lan H, Lin HV, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol. 2012 Apr;165(8):2799-807.

[3]Hothersall JD, Bussey CE, et al. Sustained wash-resistant receptor activation responses of GPR119 agonists. Eur J Pharmacol. 2015 Sep 5;762:430-42

[4]Lan H, Lin HV, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol. 2012 Apr;165(8):2799-807

MBX-2982 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.15mL

2.23mL

1.11mL

22.29mL

4.46mL

2.23mL

MBX-2982 技术信息

CAS号1037792-44-1
分子式C22H24N8OS
分子量 448.544
别名
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere,Store in freezer, under -20°C

溶解方案

DMSO: 50 mg/mL(111.47 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案一
请依序添加每种溶剂:10% DMSO 90% Corn Oil
Solubility: ≥ 2.75 mg/mL (6.13 mM); 澄清溶液
此方案可获得 ≥ 2.75 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。
动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。